AU2016354030B2 - Compositions and methods for treatment of homocystinuria - Google Patents

Compositions and methods for treatment of homocystinuria Download PDF

Info

Publication number
AU2016354030B2
AU2016354030B2 AU2016354030A AU2016354030A AU2016354030B2 AU 2016354030 B2 AU2016354030 B2 AU 2016354030B2 AU 2016354030 A AU2016354030 A AU 2016354030A AU 2016354030 A AU2016354030 A AU 2016354030A AU 2016354030 B2 AU2016354030 B2 AU 2016354030B2
Authority
AU
Australia
Prior art keywords
htcbs
leu
gly
glu
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016354030A
Other languages
English (en)
Other versions
AU2016354030A1 (en
Inventor
Erez Bublil
Jan P. Kraus
Tomas Majtan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/935,690 external-priority patent/US9675678B2/en
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Publication of AU2016354030A1 publication Critical patent/AU2016354030A1/en
Application granted granted Critical
Publication of AU2016354030B2 publication Critical patent/AU2016354030B2/en
Priority to AU2022287540A priority Critical patent/AU2022287540B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2016354030A 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria Active AU2016354030B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022287540A AU2022287540B2 (en) 2015-11-09 2022-12-12 Compositions and methods for treatment of homocystinuria

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/935,690 2015-11-09
US14/935,690 US9675678B2 (en) 2013-01-29 2015-11-09 Compositions and methods for treatment of homocystinuria
PCT/US2016/061050 WO2017083327A1 (en) 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022287540A Division AU2022287540B2 (en) 2015-11-09 2022-12-12 Compositions and methods for treatment of homocystinuria

Publications (2)

Publication Number Publication Date
AU2016354030A1 AU2016354030A1 (en) 2018-05-10
AU2016354030B2 true AU2016354030B2 (en) 2022-09-15

Family

ID=58696136

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016354030A Active AU2016354030B2 (en) 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria
AU2022287540A Active AU2022287540B2 (en) 2015-11-09 2022-12-12 Compositions and methods for treatment of homocystinuria

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022287540A Active AU2022287540B2 (en) 2015-11-09 2022-12-12 Compositions and methods for treatment of homocystinuria

Country Status (26)

Country Link
US (3) US11077175B2 (enExample)
EP (3) EP4487914A3 (enExample)
JP (2) JP7009364B2 (enExample)
KR (1) KR102819396B1 (enExample)
CN (2) CN108472277A (enExample)
AU (2) AU2016354030B2 (enExample)
BR (1) BR112018007768A2 (enExample)
CA (1) CA3001625A1 (enExample)
CY (1) CY1125113T1 (enExample)
DK (2) DK3373922T3 (enExample)
ES (2) ES2909914T3 (enExample)
FI (1) FI3998067T3 (enExample)
HR (2) HRP20241491T1 (enExample)
HU (2) HUE058749T2 (enExample)
IL (2) IL302198A (enExample)
LT (2) LT3998067T (enExample)
MX (1) MX2018005312A (enExample)
NZ (1) NZ741552A (enExample)
PL (2) PL3373922T3 (enExample)
PT (2) PT3998067T (enExample)
RS (2) RS66106B1 (enExample)
SG (1) SG10201912972SA (enExample)
SI (2) SI3998067T1 (enExample)
SM (2) SMT202400463T1 (enExample)
WO (1) WO2017083327A1 (enExample)
ZA (1) ZA201802376B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
AU2016354030B2 (en) 2015-11-09 2022-09-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
MX2019012347A (es) 2017-04-17 2020-01-15 Univ Colorado Regents Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
CN114786712A (zh) * 2019-06-26 2022-07-22 特拉维尔治疗瑞士有限公司 用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶
WO2021046190A1 (en) * 2019-09-03 2021-03-11 Orphan Technologies Ltd. Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120770A1 (en) * 2013-01-29 2014-08-07 The Regents Of University Of Colorado Cystathionine beta-synthase enzyme for treatment of homocystinuria

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS555429A (en) * 1978-06-23 1980-01-16 Nissan Motor Co Ltd Pressure regulator for fuel injection type gasoline engine
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5656425A (en) 1993-08-17 1997-08-12 Regents Of The University Of Colorado Screening for mutations by expressing cDNA segments
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
EP1221615A2 (en) 1995-04-25 2002-07-10 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
ES2224649T3 (es) 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
US6174696B1 (en) 1999-11-12 2001-01-16 Genzyme Corporation Method for the determination of homocysteine
AU5781800A (en) 1999-07-06 2001-01-22 General Atomics Methods and compositions for assaying analytes
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20030091543A1 (en) 2001-10-26 2003-05-15 Klein Matthew B. Therapeutic cell preparation grafts and methods of use thereof
WO2003106971A2 (en) 2002-06-17 2003-12-24 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE β-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) * 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
KR20060065663A (ko) 2003-07-31 2006-06-14 안티캔서, 인코포레이티드 생체 내에서의 유효성 향상을 위한, ＰＥＧ-ｒＭＥＴ아제와조합된 ＰＬＰ의 용도
CN1552905A (zh) 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070010492A1 (en) 2005-07-11 2007-01-11 Generale Robert J Composition and method for reducing homocysteine caused by drugs containing methyl compounds
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
JP6041454B2 (ja) * 2007-03-15 2016-12-07 株式会社 Ｄｎａセキュリティー研究所 Ｄｎａ含有インク組成物
JP5074146B2 (ja) 2007-03-30 2012-11-14 オリンパス株式会社 カプセル型医療装置
CN101322840A (zh) 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011097381A2 (en) 2010-02-04 2011-08-11 The Board Of Regents Of Use University Of Texas System Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
US9364497B2 (en) 2010-07-01 2016-06-14 Isis Innovation Limited Treatment of cognitive disorders
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
WO2015033279A1 (en) * 2013-09-04 2015-03-12 Mahesh Kandula Compositions and methods for the treatment of homocystinuria
CN108026143B (zh) 2015-07-24 2022-05-27 韩美药品株式会社 制备生理活性多肽缀合物的方法
AU2016354030B2 (en) 2015-11-09 2022-09-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
MX2019012347A (es) 2017-04-17 2020-01-15 Univ Colorado Regents Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
JP7002314B2 (ja) * 2017-12-13 2022-02-10 株式会社ブリヂストン 空気入りタイヤ
CN114786712A (zh) 2019-06-26 2022-07-22 特拉维尔治疗瑞士有限公司 用于治疗高胱氨酸尿症的酶疗法的PEG化胱硫醚β合成酶
WO2021046190A1 (en) 2019-09-03 2021-03-11 Orphan Technologies Ltd. Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120770A1 (en) * 2013-01-29 2014-08-07 The Regents Of University Of Colorado Cystathionine beta-synthase enzyme for treatment of homocystinuria

Also Published As

Publication number Publication date
IL302198A (en) 2023-06-01
EP3373922A4 (en) 2019-05-15
ES2994256T3 (en) 2025-01-21
PT3373922T (pt) 2022-03-28
IL258487B1 (en) 2023-05-01
EP3998067A1 (en) 2022-05-18
HRP20241491T1 (hr) 2025-01-03
KR20180074703A (ko) 2018-07-03
JP7482914B2 (ja) 2024-05-14
SI3998067T1 (sl) 2025-03-31
AU2022287540A1 (en) 2023-02-02
CN115920016A (zh) 2023-04-07
HUE058749T2 (hu) 2022-09-28
WO2017083327A1 (en) 2017-05-18
RS66106B1 (sr) 2024-11-29
PL3373922T3 (pl) 2022-05-02
LT3373922T (lt) 2022-04-11
AU2016354030A1 (en) 2018-05-10
BR112018007768A2 (pt) 2018-10-23
EP3373922A1 (en) 2018-09-19
EP3373922B1 (en) 2022-01-05
KR102819396B1 (ko) 2025-06-12
HRP20220407T1 (hr) 2022-05-27
CA3001625A1 (en) 2017-05-18
EP3998067B1 (en) 2024-09-11
US20240091325A1 (en) 2024-03-21
SG10201912972SA (en) 2020-03-30
PT3998067T (pt) 2024-11-04
EP4487914A3 (en) 2025-03-26
US12194082B2 (en) 2025-01-14
US20200276282A1 (en) 2020-09-03
SI3373922T1 (sl) 2022-05-31
DK3998067T3 (da) 2024-10-28
SMT202200151T1 (it) 2022-05-12
JP2022050589A (ja) 2022-03-30
CN108472277A (zh) 2018-08-31
SMT202400463T1 (it) 2025-01-14
HUE068830T2 (hu) 2025-01-28
CY1125113T1 (el) 2024-02-16
MX2018005312A (es) 2018-08-15
ZA201802376B (en) 2020-11-25
IL258487A (en) 2018-05-31
US11771745B2 (en) 2023-10-03
LT3998067T (lt) 2024-11-25
IL258487B2 (en) 2023-09-01
US11077175B2 (en) 2021-08-03
PL3998067T3 (pl) 2025-01-07
JP7009364B2 (ja) 2022-02-10
DK3373922T3 (da) 2022-03-28
FI3998067T3 (fi) 2024-10-31
JP2018532763A (ja) 2018-11-08
RS63070B1 (sr) 2022-04-29
ES2909914T3 (es) 2022-05-10
NZ741552A (en) 2022-04-29
AU2022287540B2 (en) 2025-02-27
EP4487914A2 (en) 2025-01-08
US20220125896A1 (en) 2022-04-28
HK1258502A1 (en) 2019-11-15

Similar Documents

Publication Publication Date Title
AU2016354030B2 (en) Compositions and methods for treatment of homocystinuria
DARKEN Puromycin inhibition of protein synthesis
Lemaitre et al. Mitotic remodeling of the replicon and chromosome structure
Lawson et al. Animal models of GM2 gangliosidosis: utility and limitations
US8999714B2 (en) Mitochondrial enhancement of cells
Marechal et al. Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a
JP2006517980A (ja) タンパク質欠損症を治療するための併用療法
Douglas et al. A requirement for Gch1 and tetrahydrobiopterin in embryonic development
KR102456795B1 (ko) 세타-디펜신들로 염증성 프로테아제들의 차단
US20090053200A1 (en) Method for retarding unhealth manifestations brought by ageing of human beings
TW205069B (enExample)
WO2012063984A1 (ko) 개량형 이듀로네이트-2-설파타제 및 이의 용도
Jaafar et al. Chromosomal anomalies and disturbance of transcriptional activity at the pachytene stage of meiosis: relationship to male sterility
AU2009282456A1 (en) Method and formulation for treating adverse biological conditions
US20160030404A1 (en) Therapeutic Agents and Methods for the Treatment of DNA Repair Deficiency Disorders
US20100316702A1 (en) Compositions and methods for regulating erythropoeitin expression and ameliorating anemia and stimulating erythropoiesis
Witherspoon et al. Mutant Nrf2E79Q enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors
US10342852B2 (en) Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein
JPWO2005054486A1 (ja) 遺伝子導入試薬調製法
Sjakste et al. Proteins tightly bound to DNA: new data and old problems
WO2021046325A1 (en) Inhibitors of sglt and uses thereof
Jiang et al. β1, 4-Galactosyltransferase V: a growth regulator in glioma
US20040176315A1 (en) Methods of identifying optimal drug combinations and compositions thereof
US20180127733A9 (en) Iduronate-2-sulfatase and use thereof
JP2003534244A (ja) 脳の化学療法におけるグルコシルセラミド合成阻害剤の使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)